A two-day meeting of the World Health Organization and the International Federation of Pharmaceutical Manufacturers Associations, held in Geneva, Switzerland, focused on the growing resistance of common infectious disease to antibiotics.
The meeting resulted in an agreement on a framework for future collaborative efforts between the WHO and the pharmaceutical industry to contain the spread of antibiotic-resistant bacteria. IFPMA executive director Richard Arnold said his members share the WHO's concerns, and that "this plan of action should be and will be supported wholeheartedly by the pharmaceutical industry."
The partnership is expected to improve opportunities for successful, cost-effective treatment of infections and to encourage research and development of new antibiotics, a WHO statement notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze